Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
PALISADE BIO, INC. (CUR)
| Date | Name | Title | Type | Security | Shares | Price | Value | Ownership | Reported |
| 10/04/2023 | Finley John David | CEO, CFO, Director | Payment of Exercise | | 397 | $0.55 | $218.4 | | 10/03/2023 |
| 10/03/2023 | Finley John David | CEO, CFO, Director | Exercise | | 1.3k | $0.00 | $0 | | 10/03/2023 |
| 09/27/2023 | Finley John David | CEO, CFO, Director | Purchase | Common Stock, par value $0.01 | 15k | $0.54 | $8.1k | | 09/27/2023 |
| 09/27/2023 | Williams Donald Allen | Director | Purchase | Common Stock, par value $0.01 | 20k | $0.54 | $10.8k | By Reporting Person's Defined Benefit Plan | 09/27/2023 |
| 08/11/2023 | Finley John David | CEO, CFO, Director | Payment of Exercise | | 1k | $0.70 | $728 | | 08/06/2023 |
| 08/06/2023 | Finley John David | CEO, CFO, Director | Exercise | | 3.5k | $0.00 | $0 | | 08/06/2023 |
| 07/06/2023 | Finley John David | CEO, CFO, Director | Payment of Exercise | | 389 | $1.76 | $686.2 | | 07/03/2023 |
| 07/03/2023 | Finley John David | CEO, CFO, Director | Exercise | | 1.3k | $0.00 | $0 | | 07/03/2023 |
| 04/03/2023 | Finley John David | CEO, CFO, Director | Exercise | | 1.3k | $0.00 | $0 | | 04/03/2023 |
| 04/03/2023 | McRae Robert Curtis | COO | Payment of Exercise | | 270 | $2.00 | $540 | | 04/03/2023 |
| 04/03/2023 | Finley John David | CEO, CFO, Director | Payment of Exercise | | 435 | $2.01 | $874.4 | | 04/03/2023 |
| 04/03/2023 | McRae Robert Curtis | COO | Exercise | | 655 | $0.00 | $0 | | 04/03/2023 |
| 02/06/2023 | Finley John David | CEO, CFO, Director | Grant | | 41.7k | $0.00 | $0 | | 02/06/2023 |
| 02/06/2023 | Finley John David | CEO, CFO, Director | Grant | | 32.5k | $0.00 | $0 | | 02/06/2023 |
| 02/06/2023 | Finley John David | CEO, CFO, Director | Grant | | 57.2k | $2.40 | $137.3k | | 02/06/2023 |
| 01/03/2023 | Finley John David | CEO, CFO, Director | Grant | | 5.2k | $0.00 | $0 | | 01/03/2023 |
| 09/01/2022 | Finley John David | CEO, CFO, Director | Purchase | Common Stock, par value $0.01 | 19.5k | $0.14 | $2.8k | | 09/01/2022 |
| 08/23/2022 | Finley John David | CEO, CFO, Director | Purchase | Common Stock, par value $0.01 | 7.4k | $0.16 | $1.2k | | 08/23/2022 |
| 08/16/2022 | Finley John David | CEO, CFO, Director | Purchase | Common Stock, par value $0.01 | 100k | $0.25 | $25k | | 08/16/2022 |
| 08/16/2022 | Finley John David | CEO, CFO, Director | Purchase | Series 2 Common Stock Purchase Warrant | 100k | $0.25 | $25k | | 08/16/2022 |
| 08/16/2022 | Hallam Thomas | CEO | Purchase | Common Stock, par value $0.01 | 40k | $0.25 | $10k | | 08/16/2022 |
| 08/16/2022 | Hallam Thomas | CEO | Purchase | Series 2 Common Stock Purchase Warrant | 40k | $0.25 | $10k | | 08/16/2022 |
| 04/29/2022 | Finley John David | CEO, CFO, Director | Other (acquisition) | Common Stock | 12.5k | $0.00 | $0 | By FCW Investments LLC | 04/29/2022 |
| 03/29/2022 | Dawson Michael John | Chief Medical Officer | Purchase | Common Stock | 15k | $1.14 | $17.1k | | 03/29/2022 |
| 03/28/2022 | Hallam Thomas | CEO | Purchase | Common Stock | 10k | $1.18 | $11.8k | | 03/28/2022 |
| 03/24/2022 | Finley John David | CEO, CFO, Director | Purchase | Common Stock | 7.5k | $1.09 | $8.2k | | 03/24/2022 |
| 02/17/2022 | Dawson Michael John | Chief Medical Officer | Grant | Stock Option (right to buy) | 32.4k | $0.95 | $30.8k | | 02/17/2022 |
| 02/17/2022 | Hallam Thomas | CEO | Grant | Stock Option (right to buy) | 156.6k | $0.95 | $148.8k | | 02/17/2022 |
| 02/17/2022 | Finley John David | CEO, CFO, Director | Grant | Stock Option (right to buy) | 64.8k | $0.95 | $61.6k | | 02/17/2022 |
| 11/18/2021 | Wei Binxian | Director | Grant | Stock Option (right to buy) | 48.3k | $2.32 | $112.1k | | 11/18/2021 |
| 11/18/2021 | Hallam Thomas | CEO | Grant | Stock Option (right to buy) | 267.9k | $2.32 | $621.5k | | 11/18/2021 |
| 11/18/2021 | Trenschel Robert J. | Director | Grant | Stock Option (right to buy) | 48.3k | $2.32 | $112.1k | | 11/18/2021 |
| 11/18/2021 | GRAY MARY ANN | Director | Grant | Stock Option (right to buy) | 48.3k | $2.32 | $112.1k | | 11/18/2021 |
| 11/18/2021 | Dawson Michael John | Chief Medical Officer | Grant | Stock Option (right to buy) | 39.3k | $2.32 | $91.2k | | 11/18/2021 |
| 11/18/2021 | Diaz Stephanie | Director | Grant | Stock Option (right to buy) | 48.3k | $2.32 | $112.1k | | 11/18/2021 |
|
|